This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Middlebrooks, MD, Mayo Clinic, Jacksonville, FL Erik H. Middlebrooks, MD, of the Mayo Clinic in Jacksonville, FL. He earned his medical degree at the University of Alabama School of Medicine and completed a residency in diagnostic radiology at the University of Florida. Middlebrooks, MD.
The new horizons of advanced imaging, especially in oncology, must increasingly consider not only diagnostic efficacy but also sustainability for patients, prize-winning researchers told ECR 2025 delegates. To mitigate these effects, low-energy imaging techniques should be prioritized without compromising diagnostic accuracy.
The company has entered into asset purchase and exclusive worldwide in-license agreements for a suite of clinically validated FAP-targeting therapeutic and precision medicine radiopharmaceutical candidates.
Flyrcado delivers higher diagnostic efficacy compared with standard SPECT MPI,GE said. Pass-through payment status will allow the CMS to provide separate payments for the radiopharmaceutical and the PET-CT scan when performed with Flyrcado in the hospital outpatient setting. Food and Drug Administration (FDA) for the injection in 2024.Flyrcadois
A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers, according to research presented at the American Society for Radiation Oncology (ASTRO) meeting. Nearly 80% of patients in our study were progression-free after six months," he said.
Most Influential Radiology Researcher Erik Middlebrooks, MD, Mayo Clinic, Jacksonville, FL Erik Middlebrooks, MD. One of this year's nominations for Most Influential Radiology Researcher is Erik Middlebrooks, MD, of the Mayo Clinic in Jacksonville, FL. He served in the U.S. He earned his medical degree from Washington University in St.
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. At the time, their cancer center served a significant cancer population in the region and maintained robust and ever-expanding PET diagnostics.
Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.
Blue Earth Diagnostics is highlighting results from a clinical study that ha. prostate radiopharmaceutical licensing Blue Earth to highlight PET study results at ASTRO Blue Earth wins FDA nod for PSMA-PET tracer NDA
announced that it has entered into a patent license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate. We focused on diagnostic accuracy, patient tolerance and convenience.
and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. Our ongoing Phase 1/2 clinical trial ( NCT05413850 ) is evaluating 177Lu-rhPSMA-10.1
In patients treated at a memory clinic at Huashan Hospital in Shanghai, amyloid PET scans detected brain pathology associated with the disease and led to changes in treatment plans in 36.5% The clinical utility of amyloid PET scans has been systematically studied in many other countries. The full study is available here.
Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Board of Directors.
a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.
By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."
MIBI-SPECT/CT is considered the standard technique for guiding these surgeries, yet several phase II clinical trials suggest advantages of a newer approach using FCH-PET, such as superior spatial resolution for detecting small adenomas and lower radiation exposure to patients, they noted. The full study is available here.
The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.
NorthStar Medical Radioisotopes and Chester Springs, PA-based Curadh MTR have entered a strategic collaboration agreement to develop radiopharmaceuticals for the treatment of primary and metastatic solid tumors.
POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,
Flyrcado delivers higher diagnostic efficacy compared with standard SPECT MPI,GE said. Pass-through payment status will allow the CMS to provide separate payments for the radiopharmaceutical and the PET-CT scan when performed with Flyrcado in the hospital outpatient setting. Food and Drug Administration (FDA) for the injection in 2024.Flyrcadois
ITM Isotope Technologies Munich has signed a licensing agreement with the life science business of Merck KGaA in Darmstadt, Germany, for the clinical development and commercialization of radiolabeled folate derivatives. The company plans to advance this to phase I clinical testing.
We are delighted by our collaboration with Ratio Therapeutics in advancing the clinical development of RTX-1363S as a FAP-targeted diagnostic to the clinic," stated Etienne Montagut, Lantheus' Chief Business Officer. "By RTX-1363S has the potential to transform the way we detect and monitor various epithelial-derived cancers."
Blue Earth Diagnostics, a Bracco company, is highlighting results from a stud. Read more on AuntMinnie.com Related Reading: FDA approves new PET tracer for prostate cancer imaging Blue Earth touts clinical results PET tracer shows promise in imaging of brain tumors Blue Earth touts PSMA radiotracer study Blue Earth moves toward U.K.
Food and Drug Administration (FDA) has approved Blue Earth Diagnostics. Read more on AuntMinnie.com Related Reading: Blue Earth touts clinical results Blue Earth highlights results from PET tracer trial PET tracer shows promise in imaging of brain tumors Blue Earth touts PSMA radiotracer study Blue Earth moves toward U.K.
milla1cf Fri, 09/08/2023 - 16:25 September 8, 2023 — Positron Corporation , a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity PET-CT imaging device with Ochsner Clinic Foundation in New Orleans, LA. on September 18, 2023.
Lantheus Holdings plans to acquire theranostic radiopharmaceutical manufacturer Evergreen Theragnostics for an upfront payment of $250 million and up to $752.5 million in potential milestone payments. The transaction is expected to close in the second half of 2025, according to Lantheus.
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, and PSI CRO, a global contract research organization, plan to conduct a trial using Clarity's phase III diagnostic trial of Clarify for prostate cancer patients.
milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1
Assessment of Claimant, Clinical, and Financial Characteristics of Teleradiology Medical Malpractice Cases. Central Vein Sign in Multiple Sclerosis: A Comparison Study of the Diagnostic Performance of 3T versus 7T MRI. Francisco, et al, Emergency Radiology , April 26, 2024. To learn more about this paper, click here.
68Ga-DOTA-RM2 will be used as a companion diagnostic. While new PSMA-targeted diagnostics and therapeutics are transforming prostate cancer care, there are many patients for whom PSMA-targeted therapy may not be appropriate,” said Brian Markison, Lantheus CEO.
milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 on behalf of the SPOTLIGHT Study Group.
The Care Innovation Hub leverages the strengths of academia and industry to create, evaluate and translate novel technology into a clinical setting with the goals of advancing diagnosis and treatment of disease, improving hospital operations and driving more equitable access to care. tim.hodson Mon, 01/27/2025 - 10:11 Jan.
PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Chief Executive Officer of Blue Earth Diagnostics. from October 1 to 4, 2023. Gauden , D.Phil., Kuo, MD, Ph.D.,
POSLUMA is now commercially available through multiple radiopharmacies of PETNET Solutions, the primary manufacturer and commercial distributor for Blue Earth Diagnostics in the United States. Chief Executive Officer of Blue Earth Diagnostics Ltd. Blue Earth Diagnostics is at Booth 6025 and PETNET Solutions is at Booth 6075.
A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. They're also mindful of the multiple dedicated teams required to build a theranostics clinic properly. However, few freestanding theranostics centers exist today.
“The ROCR Act will increase access to lifesaving cancer treatments, incentivize high-value care, address disparities that undermine patient outcomes and provide a path to financial stability for radiation oncology clinics,” according to an ASTRO statement. payment cut for 2025 and provide an inflation-adjusted update.”
Efforts to bring quantitative MRI analysis into clinical practice received a boost with the availability of two new Category III Current Procedural Terminology (CPT) codes for brain MRI. As such, radiopharmaceuticals consisting of a TSPO ligand coupled to a PET radioisotope serve as effective imaging agents for neuroinflammation.
Radiotheranostic treatments combine diagnostic imaging with targeted radiopharmaceutical therapy, providing personalised cancer care with enhanced precision and effectiveness. The post Radiotheranostic Treatments: A Guide to Types and Their Clinical Applications appeared first on Open MedScience.
Life Molecular Imaging and PharmaLogic Holdings have inked a partnership and licensing agreement to provide and distribute the imaging agent Neuraceq from PharmaLogic's radiopharmaceutical manufacturing site near Denver, CO. Neuraceq is a diagnostic agent cleared by the U.S.
milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content